Literature DB >> 12454802

Association between the severity of angiographic coronary artery disease and paraoxonase gene polymorphisms in the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation (WISE) study.

Qi Chen1, Steven E Reis, Candace M Kammerer, Dennis M McNamara, Richard Holubkov, Barry L Sharaf, George Sopko, Daniel F Pauly, C Noel Bairey Merz, M Ilyas Kamboh.   

Abstract

Paraoxonase (PON), a high-density lipoprotein-associated enzyme, is believed to protect against low-density lipoprotein oxidation and thus affects the risk of coronary artery disease (CAD). Three polymorphisms in the PON1 (Leu55Met and Gln192Arg) and PON2 (Ser311Cys) genes have been shown to be associated with the risk of CAD in several European or European-derived populations. In the present study, we examined the associations between these three markers and the severity of CAD as determined by the number of diseased coronary artery vessels in 711 subjects (589 whites and 122 blacks) from the Women's Ischemia Syndrome Evaluation (WISE) study. WISE is a National Heart, Lung, and Blood Institute-sponsored multicenter study designed to address issues related to ischemic-heart-disease recognition and diagnosis in women. Subjects were classified as having normal/minimal CAD (<20% stenosis), mild CAD (20%-49% stenosis), and significant CAD (>/=50% stenosis). The women who had >/=50% stenosis were further classified into groups with one-, two-, or three-vessel disease if any of the three coronary arteries had diameter stenosis >/=50%. No significant association was found between the PON polymorphisms and stenosis severity in either white or black women. However, among white women, when data were stratified by the number of diseased vessels, the frequency of the PON1 codon 192 Arg/Arg genotype was significantly higher in the group with three-vessel disease than in the other groups (those with one-vessel and two-vessel disease) combined (17.02% vs. 4.58%; P=.0066). Similarly, the frequency of the PON2 codon 311 Cys/Cys genotype was significantly higher in the group with three-vessel disease than in the other groups combined (15.22% vs. 4.61%; P=.018). The adjusted odds ratios for the development of three-vessel disease were 2.80 (95% confidence interval 1.06-7.37; P=.038) for PON1 codon 192 Arg/Arg and 3.68 (95% confidence interval 1.26-10.68; P=.017) for PON2 codon 311 Cys/Cys. Our data indicate that the severity of CAD, in terms of the number of diseased vessels, may be affected by common genetic variation in the PON gene cluster, on chromosome 7.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12454802      PMCID: PMC378617          DOI: 10.1086/345312

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  53 in total

1.  Association between obesity and coronary atherosclerosis and vascular remodeling.

Authors:  J Al Suwaidi; S T Higano; S Hamasaki; D R Holmes; A Lerman
Journal:  Am J Cardiol       Date:  2001-12-01       Impact factor: 2.778

2.  Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids.

Authors:  S T Reddy; D J Wadleigh; V Grijalva; C Ng; S Hama; A Gangopadhyay; D M Shih; A J Lusis; M Navab; A M Fogelman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-04       Impact factor: 8.311

Review 3.  Lipoproteins and the pathogenesis of atherosclerosis.

Authors:  D Steinberg; T E Carew; C Fielding; A M Fogelman; R W Mahley; A D Sniderman; D B Zilversmit
Journal:  Circulation       Date:  1989-09       Impact factor: 29.690

4.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

5.  Type 2 diabetes and three calpain-10 gene polymorphisms in Samoans: no evidence of association.

Authors:  H J Tsai; G Sun; D E Weeks; R Kaushal; M Wolujewicz; S T McGarvey; J Tufa; S Viali; R Deka
Journal:  Am J Hum Genet       Date:  2001-11-05       Impact factor: 11.025

6.  Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein.

Authors:  M I Mackness; S Arrol; P N Durrington
Journal:  FEBS Lett       Date:  1991-07-29       Impact factor: 4.124

7.  The association of risk factors with arteriographically defined coronary artery disease: what is the appropriate control group?

Authors:  L P Fried; T A Pearson
Journal:  Am J Epidemiol       Date:  1987-05       Impact factor: 4.897

8.  Predictors of arteriographically defined coronary stenosis in the Honolulu Heart Program. Comparisons of cohort and arteriography series analyses.

Authors:  D Reed; K Yano
Journal:  Am J Epidemiol       Date:  1991-07-15       Impact factor: 4.897

9.  Invited commentary: should arteriographic case-control studies be used to identify causes of atherosclerotic coronary artery disease?

Authors:  T A Pearson; C A Derby
Journal:  Am J Epidemiol       Date:  1991-07-15       Impact factor: 4.897

10.  High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.

Authors:  D J Gordon; J L Probstfield; R J Garrison; J D Neaton; W P Castelli; J D Knoke; D R Jacobs; S Bangdiwala; H A Tyroler
Journal:  Circulation       Date:  1989-01       Impact factor: 29.690

View more
  37 in total

Review 1.  New advances in identifying genetic anomalies in stroke-prone probands.

Authors:  James F Meschia; Bradford B Worrall
Journal:  Curr Atheroscler Rep       Date:  2003-07       Impact factor: 5.113

Review 2.  Paraoxonase 1, atherosclerosis and arterial stiffness in renal patients.

Authors:  Ozkan Gungor; Fatih Kircelli; Huseyin Toz
Journal:  Int Urol Nephrol       Date:  2012-06-06       Impact factor: 2.370

3.  New advances in identifying genetic anomalies in stroke-prone probands.

Authors:  James F Meschia; Bradford B Worrall
Journal:  Curr Neurol Neurosci Rep       Date:  2004-09       Impact factor: 5.081

4.  Association of two polymorphisms in the FADS1/FADS2 gene cluster and the risk of coronary artery disease and ischemic stroke.

Authors:  Qian Yang; Rui-Xing Yin; Xiao-Li Cao; Dong-Feng Wu; Wu-Xian Chen; Yi-Jiang Zhou
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

Review 5.  The paraoxonase gene family and atherosclerosis.

Authors:  David Seo; Pascal Goldschmidt-Clermont
Journal:  Curr Atheroscler Rep       Date:  2009-05       Impact factor: 5.113

Review 6.  Paraoxonase-2 (PON2) in brain and its potential role in neuroprotection.

Authors:  Lucio G Costa; Rian de Laat; Khoi Dao; Claudia Pellacani; Toby B Cole; Clement E Furlong
Journal:  Neurotoxicology       Date:  2013-09-04       Impact factor: 4.294

7.  Paraoxonases-1, -2 and -3: What are their functions?

Authors:  Clement E Furlong; Judit Marsillach; Gail P Jarvik; Lucio G Costa
Journal:  Chem Biol Interact       Date:  2016-05-26       Impact factor: 5.192

8.  Effect of efavirenz on high-density lipoprotein antioxidant properties in HIV-infected patients.

Authors:  S A Pereira; J R Batuca; U Caixas; T Branco; J Delgado-Alves; I Germano; F Lampreia; E C Monteiro
Journal:  Br J Clin Pharmacol       Date:  2009-12       Impact factor: 4.335

Review 9.  Paraoxonase gene polymorphisms, oxidative stress, and diseases.

Authors:  Hong-Liang Li; De-Pei Liu; Chih-Chuan Liang
Journal:  J Mol Med (Berl)       Date:  2003-10-09       Impact factor: 4.599

10.  A common mutation in paraoxonase-2 results in impaired lactonase activity.

Authors:  David A Stoltz; Egon A Ozer; Thomas J Recker; Miriam Estin; Xia Yang; Diana M Shih; Aldons J Lusis; Joseph Zabner
Journal:  J Biol Chem       Date:  2009-12-18       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.